Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Hematological Response to Eculizumab in Paroxysmal Nocturnal Hemoglobinuria: Application of a Novel Classification to Identify Unmet Clinical Needs and Future Clinical Goals

Pierre-Edouard Debureaux, MD, Fabiana Cacace, Bruno G.P. Silva, MD, Federica Barone, MD, Rodrigo T Calado, MD, Flore Sicre de Fontbrune, Juliette Soret-Dulphy, MD, Patrizia Ricci, Michela Sica, PhD, Rosario Notaro, MD, Phillip Scheinberg, MD, Austin Kulasekararaj, MDMBBS,MRCP,FRCPath, Antonio M. Risitano, MD PhD, Régis Peffault de Latour, MD PhD, Camilla Frieri, MD

Blood (2019) 134 (Supplement_1): 3517.

https://doi.org/10.1182/blood-2019-125917

Published: 2019

Journal Articles

Two Distinct but Functionally Related Autoreactive T Cell Populations in Paroxysmal Nocturnal Hemoglobinuria and Idiopathic Aplastic Anemia: Glycosylphosphatidylinositol-Specific and IFNγ-Producing T Cells

Lucia Gargiulo, PhD, Michela Sica, PhD, Caterina Nannelli, BSc, Lucio Luzzatto, MD, Rosario Notaro, MD

Blood (2017) 130 (Supplement 1): 1166.

https://doi.org/10.1182/blood.V130.Suppl_1.1166.1166

Published: 2017

Journal Articles

CD59 Deficiency Is Critical for C3 Binding on Red Blood Cells of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) during Anti-C5 Treatment (eculizumab)

MIchela Sica, PhD, Tommaso Rondelli, Patrizia Ricci, PhD, Maria De Angioletti, PhD, Antonio M Risitano, MD PhD, Rosario Notaro, MD

Blood (2016) 128 (22): 401.

https://doi.org/10.1182/blood.V128.22.401.401

Published: 2016

Journal Articles

Complement Activation in Paroxysmal Nocturnal Hemoglobinuria (PNH) Causes Oxidative Damage Which May Affect Response to Eculizumab

Michela Sica, PhD, Annamaria Pellecchia, PhD, Margherita Berardi, BS, Lucia Gargiulo, PhD, Tolulase A Olutogun, MD, Giovanni Caocci, MD, Giorgio La Nasa, MD, Maria De Angioletti, PhD, Lucio Luzzatto, MD FRCP, FRCPath, Rosario Notaro, MD

Blood (2014) 124 (21): 4397.

https://doi.org/10.1182/blood.V124.21.4397.4397

Published: 2014

Journal Articles

Autoreactive T Cells From Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Specifically Recognize Glycosyl- Phosphatidyl-Inositol (GPI)

Lucia Gargiulo, PhD, Michela Sica, PhD, Maria Papaioannou, MD, PhD, Giulia Talini, PhD, Aristeidis Chaidos, MD, PhD, Barbara Richichi, PhD, Andrei V Nikolaev, PhD, Cristina Nativi, PhD, Mark Layton, MD, Josu de la Fuente, MRCP, MRCPCH, FRCPath, Irene Roberts, Lucio Luzzatto, MD, FRCP, FRCPath, Rosario Notaro, MD, Anastasios Karadimitris, MD, PhD

Blood (2012) 120 (21): 647.

https://doi.org/10.1182/blood.V120.21.647.647

Published: 2012

Journal Articles

Novel Complement Modulators for Paroxysmal Nocturnal Hemoglobinuria: Peptide and Protein Inhibitors of C3 Convertase Prevent Both Surface C3 Deposition and Subsequent Hemolysis of Affected Erythrocytes in Vitro

Antonio M. Risitano, MD, PhD, Patrizia Ricci, Caterina Pascariello, Maddalena Raia, Christoph Q Schmidt, Yingxue Li, Edimara S Reis, Michela Sica, PhD, Rosario Notaro, MD, Luigi Del Vecchio, MD, Fabrizio Pane, Daniel Ricklin, John D Lambris

Blood (2012) 120 (21): 370.

https://doi.org/10.1182/blood.V120.21.370.370

Published: 2012

NARROW

Hematological Response to Eculizumab in Paroxysmal Nocturnal Hemoglobinuria: Application of a Novel Classification to Identify Unmet Clinical Needs and Future Clinical Goals

Two Distinct but Functionally Related Autoreactive T Cell Populations in Paroxysmal Nocturnal Hemoglobinuria and Idiopathic Aplastic Anemia: Glycosylphosphatidylinositol-Specific and IFNγ-Producing T Cells

CD59 Deficiency Is Critical for C3 Binding on Red Blood Cells of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) during Anti-C5 Treatment (eculizumab)

Complement Activation in Paroxysmal Nocturnal Hemoglobinuria (PNH) Causes Oxidative Damage Which May Affect Response to Eculizumab

Autoreactive T Cells From Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Specifically Recognize Glycosyl- Phosphatidyl-Inositol (GPI)

Novel Complement Modulators for Paroxysmal Nocturnal Hemoglobinuria: Peptide and Protein Inhibitors of C3 Convertase Prevent Both Surface C3 Deposition and Subsequent Hemolysis of Affected Erythrocytes in Vitro

Email alerts

ASH Publications

American Society of Hematology

Hematological Response to Eculizumab in Paroxysmal Nocturnal Hemoglobinuria: Application of a Novel Classification to Identify Unmet Clinical Needs and Future Clinical Goals

Two Distinct but Functionally Related Autoreactive T Cell Populations in Paroxysmal Nocturnal Hemoglobinuria and Idiopathic Aplastic Anemia: Glycosylphosphatidylinositol-Specific and IFNγ-Producing T Cells

CD59 Deficiency Is Critical for C3 Binding on Red Blood Cells of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) during Anti-C5 Treatment (eculizumab)

Complement Activation in Paroxysmal Nocturnal Hemoglobinuria (PNH) Causes Oxidative Damage Which May Affect Response to Eculizumab

Autoreactive T Cells From Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Specifically Recognize Glycosyl- Phosphatidyl-Inositol (GPI)

Novel Complement Modulators for Paroxysmal Nocturnal Hemoglobinuria: Peptide and Protein Inhibitors of C3 Convertase Prevent Both Surface C3 Deposition and Subsequent Hemolysis of Affected Erythrocytes in Vitro

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only